



Drug Quantity Management – Per Rx Antidepressants – Serotonin and Norepinephrine Reuptake Inhibitors

Table of Contents

National Formulary Medical Necessity	1
Conditions Not Covered.....	9
Background.....	9
References	10
Revision History.....	10

Product Identifier(s)

Effective 1/1/23 to 2/6/23:
107938, 108237, 111402, 107957, 108855

Effective 2/7/23:
34181, 34215, 34255, 35672, 38526

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

Drugs Affected

- Cymbalta® (duloxetine delayed-release capsules – generic)
- Desvenlafaxine extended-release tablets [brand product]
- Drizalma Sprinke™ (duloxetine delayed-release capsules)
- Duloxetine 40 mg delayed-release capsules (generic only)
- Effexor® XR (venlafaxine extended-release capsules – generic)
- Fetzima® (levomilnacipran extended-release capsules)
- Khedezla™ (desvenlafaxine extended-release tablets – discontinued)
- Pristiq® (desvenlafaxine succinate extended-release tablets – generic)
- Savella® (milnacipran tablets)
- Venlafaxine besylate extended-release tablets [brand product]
- Venlafaxine hydrochloride tablets (generic only)
- Venlafaxine hydrochloride extended-release tablets (generic only)

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of the serotonin and norepinephrine reuptake inhibitors. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration unless otherwise noted below.

Drug Quantity Limits

Brand (generic)	FDA-Approved Dosing	Availability	Retail Maximum Quantity per Rx ^a	Home Delivery Maximum Quantity per Rx ^a
Cymbalta® (duloxetine delayed-release capsules, generic)	<ul style="list-style-type: none"> • <u>MDD</u>: 20 mg BID to 60 mg/day (given either BID or QD). May start with 30 mg QD x 1 week before increasing to 60 mg/day. • <u>Fibromyalgia and chronic musculoskeletal pain</u>: 30 mg/day. • <u>GAD and DPNP pain</u>: 60 mg QD. May use 30 mg QD for elderly or pediatric patients. • Maximum doses range from 60 mg to 120 mg/day. 	20 mg capsules	60 capsules	180 capsules
		30 mg capsules	30 capsules	90 capsules
		60 mg capsules	60 capsules	180 capsules

Drug Quantity Limits (continued)

Brand (generic)	FDA-Approved Dosing	Availability	Retail Maximum Quantity per Rx ^a	Home Delivery Maximum Quantity per Rx ^a
duloxetine delayed-release capsules (generic to discontinued Irenka™)	<ul style="list-style-type: none"> • <u>MDD</u>: 20 mg BID to 60 mg/day (given either BID or QD). May start with 30 mg QD x 1 week before increasing to 60 mg/day. • <u>Chronic musculoskeletal pain</u>: 60 mg/day. Begin with 30 mg/day for 1 week prior to increasing to 60 mg/day. • <u>GAD and DPNP pain</u>: 60 mg QD. May use 30 mg QD for elderly or pediatric patients. • Maximum doses range from 60 mg to 120 mg/day. 	40 mg capsules	30 capsules	90 capsules
Drizalma Sprinkle™ (duloxetine delayed-release capsules)	<ul style="list-style-type: none"> • <u>MDD</u>: 20 mg BID to 60 mg/day (given either BID or QD). May start with 30 mg QD x 1 week before increasing to 60 mg/day. • <u>Fibromyalgia and chronic musculoskeletal pain</u>: 30 mg/day. • <u>GAD and DPNP pain</u>: 60 mg QD. May use 30 mg QD for elderly or pediatric patients. • Maximum doses range from 60 mg to 120 mg/day. 	20 mg capsules	60 capsules	180 capsules
		30 mg capsules	30 capsules	90 capsules
		40 mg capsules	60 capsules	180 capsules
		60 mg capsules	30 capsules	90 capsules
Desvenlafaxine extended-release tablets (brand product)	<ul style="list-style-type: none"> • <u>MDD</u>: 50 mg QD (starting dose and therapeutic dose). Doses of 10 mg to 400 mg/day have been studied and were shown to be effective. However, no additional benefit was demonstrated at doses > 50 mg/day and AEs and discontinuations were more frequent at higher doses. 	50 mg tablets	30 tablets	90 tablets
		100 mg tablets	30 tablets	90 tablets

	<ul style="list-style-type: none"> Maximum dose in severe renal impairment or ESRD is 25 mg QD or 50 mg every other day. 			
Khedezla™ (desvenlafaxine extended-release tablets)	<ul style="list-style-type: none"> MDD: 50 mg QD (starting dose and therapeutic dose). Doses of 10 mg to 400 mg/day have been studied and were shown to be effective. However, no additional benefit was demonstrated at doses > 50 mg/day and AEs and discontinuations were more frequent at higher doses. Maximum dose in severe renal impairment or ESRD is 25 mg QD or 50 mg every other day. 	50 mg tablets	30 tablets	90 tablets
		100 mg tablets	30 tablets	90 tablets

Drug Quantity Limits (continued)

Brand (generic)	FDA-Approved Dosing	Availability	Retail Maximum Quantity per Rx ^a	Home Delivery Maximum Quantity per Rx ^a
Pristiq® (desvenlafaxine succinate extended-release tablets, generic)	<ul style="list-style-type: none"> MDD: 50 mg QD (starting dose and therapeutic dose). Doses of 10 mg to 400 mg/day have been studied and were shown to be effective. However, no additional benefit was demonstrated at doses > 50 mg/day and AEs and discontinuations were more frequent at higher doses. Maximum dose in severe renal impairment or ESRD is 25 mg QD or 50 mg every other day. 	25 mg tablets	30 tablets	90 tablets
		50 mg tablets	30 tablets	90 tablets
		100 mg tablets	30 tablets	90 tablets
venlafaxine HCl immediate-release tablets (generic to discontinued Effexor®)	<ul style="list-style-type: none"> MDD: 75 mg/day (administered in 2 to 3 divided doses). May be increased (in 75 mg/day increments) to 150 mg/day and further increased to 225 mg/day based on tolerability and desired effect. Doses of up to 350 mg to 375 mg/day (in three divided doses) have been studied in severely depressed patients. Reduce the total daily dose by 25% in patients with renal impairment. Reduce the dose by 50% in patients with mild to moderate hepatic impairment or those undergoing hemodialysis. 	25 mg tablets	90 tablets	270 tablets
		37.5 mg tablets	90 tablets	270 tablets
		50 mg tablets	90 tablets	270 tablets
		75 mg tablets	90 tablets	270 tablets
		100 mg tablets	90 tablets	270 tablets
Effexor XR® (venlafaxine HCl extended-release capsules, generic)	<ul style="list-style-type: none"> MDD and GAD: 75 mg/day. Some patients may start at 37.5 mg/day for 4 to 7 days before increasing to 75 mg/day. If not responding to 75 mg/day, may increase dose up to 225 mg/day in increments of 75 mg/day as needed. Average dose is 350 mg/day (range 150 mg to 375 mg/day). Social Anxiety Disorder: 75 mg/day. 	37.5 mg capsules	30 capsules	90 capsules
		75 mg capsules	90 capsules	270 capsules
		150 mg capsules	30 capsules	90 capsules

	<ul style="list-style-type: none"> • <u>Panic disorder</u>: 37 mg/day x 7 days, then 75 mg/day up to a maximum of 225 mg/day (increased in 75 mg/day increments as needed). • Reduce dose by 25% to 50% for patients with mild or moderate renal impairment and by 50% in patients with severe hepatic impairment, hepatic cirrhosis, or those with severe renal impairment/undergoing hemodialysis. 			
--	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--

Drug Quantity Limits (continued)

Brand (generic)	FDA-Approved Dosing	Availability	Retail Maximum Quantity per Rx ^a	Home Delivery Maximum Quantity per Rx ^a
Venlafaxine HCl extended-release tablets (generic only)	<ul style="list-style-type: none"> • <u>MDD</u>: 75 mg QD. Some patients may start at 37.5 mg QD for 4-7 days before increasing. If no response to the initial dose, may increase up to 225 mg QD in increments of 75 mg/day) 350 mg/day (range 150 mg to 275 mg/day) has been studied in more severely depressed patients. • <u>Social Anxiety Disorder</u>: 75 mg QD. • Reduce dose by 25% to 50% for patients with mild or moderate renal impairment and by 50% in patients with severe hepatic impairment, hepatic cirrhosis, or those with severe renal impairment/undergoing hemodialysis. 	37.5 mg tablets	30 tablets	90 tablets
		75 mg tablets	30 tablets	90 tablets
		150 mg tablets	30 tablets	90 tablets
		225 mg tablets	30 tablets	90 tablets
Venlafaxine besylate extended-release tablets (brand product)	<p><u>This product is only available as a 112.5 mg tablet, therefore, use another venlafaxine extended-release product for dose initiation, titration, and administration of doses less than 112.5 mg QD. Tablets should be swallowed whole; do not divide, crush, chew, or place in water prior to administration.</u></p> <ul style="list-style-type: none"> • <u>MDD and GAD</u>: 112.5 mg QD in patients who have received at least 75 mg per day of another venlafaxine extended-release product for at least 4 days. If the patient is not responding to their current venlafaxine dose, they may benefit from a dose increase to a maximum of 225 mg per day. The dose should be increased in increments of up to 75 mg per day, as needed, using another venlafaxine extended-release 	112.5 mg tablets	30 tablets	90 tablets

	product, at intervals of 4 days or more.			
Fetzima® (levomilnacipran extended-release capsules)	<ul style="list-style-type: none"> • MDD: 40 mg to 120 mg QD (starting at 20 mg QD, increased to 40 mg QD, then increased in 40 mg/day intervals) • Maximum dose in moderate renal impairment is 80 mg QD and in severe renal impairment the dose should not exceed 40 mg QD. 	20 mg capsules	30 capsules	90 capsules
		40 mg capsules	30 capsules	90 capsules
		80 mg capsules	30 capsules	90 capsules
		120 mg capsules	30 capsules	90 capsules
		Titration Pack (2 x 20 mg capsules and 26 x 40 mg capsules)	1 pack (28 capsules)	1 pack (28 capsules)

Drug Quantity Limits (continued)

Brand (generic)	FDA-Approved Dosing	Availability	Retail Maximum Quantity per Rx ^a	Home Delivery Maximum Quantity per Rx ^a
Savella® (milnacipran tablets)	Titrate Savella according to the following schedule (based on efficacy and tolerability): <ul style="list-style-type: none"> • Day 1: 12.5 mg once • Days 2-3: 12.5 mg BID • Days 4-7 25 mg BID • After Day 7: 50 mg BID • May increase to 100 mg BID based on individual patient response. • In patients with severe renal impairment, the maintenance dose should be reduced by 50% to 25 mg BID and may be increased to 50 mg BID based on individual response. 	12.5 mg tablets	60 tablets	180 tablets
		25 mg tablets	60 tablets	180 tablets
		50 mg tablets	60 tablets	180 tablets
		100 mg tablets	60 tablets	180 tablets
		Titration Pack (5 x 12.5-mg tablets, 8 x 25-mg tablets, and 42 x 50 mg tablets)	1 pack (55 tablets)	1 pack (55 tablets)

^a When possible, the patient should be referred to higher strength capsule/tablet if a higher dose is needed. MDD – Major depressive disorder; BID – Twice daily; QD – Once daily; GAD – Generalized Anxiety Disorder; DPNP – Diabetic peripheral neuropathy pain; ESRD – End-stage renal disease.

Criteria

Cigna covers quantities as medically necessary when the following criteria are met:

Duloxetine 20 mg delayed-release capsules (Cymbalta, generic), Drizalma Sprinkle 20 mg delayed-release capsules

1. If the individual is taking 40 mg twice daily, approve 120 capsules as a 30-day supply per dispensing at retail and 360 capsules as a 90-day supply per dispensing at home delivery.
2. If the individual is taking 20 mg three times daily or is taking a 40 mg dose and a 20 mg dose per day, approve 90 capsules as a 30-day supply per dispensing at retail and 270 capsules as a 90-day supply per dispensing at home delivery.
3. If the individual is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve a quantity sufficient to allow for a 30-day supply per dispensing at retail, and a 90-day supply per dispensing at home delivery, not to exceed a dose of 120 mg per day.

Duloxetine 30 mg delayed-release capsules (Cymbalta, generic), Drizalma Sprinkle 30 mg delayed-release capsules

1. If the individual is taking 30 mg twice daily, approve 60 capsules as a 30-day supply per dispensing at retail and 180 capsules as a 90-day supply per dispensing at home delivery.
2. If the individual is taking 30 mg three times daily or is taking a 60 mg dose and a 30 mg dose per day, approve 90 capsules as a 30-day supply per dispensing at retail and 270 capsules as a 90-day supply per dispensing at home delivery.
3. If the individual is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve a quantity sufficient to allow for a 30-day supply per dispensing at retail, and a 90-day supply per dispensing at home delivery, not to exceed a dose of 120 mg per day.

Duloxetine 40 mg delayed-release capsules (generic to discontinued Irenka), Drizalma Sprinkle 40 mg delayed-release capsules

1. *If the individual is taking a dose of 80 mg per day, approve 60 capsules as a 30-day supply per dispensing at retail and 180 capsules as a 90-day supply per dispensing at home delivery.*

Duloxetine 60 mg delayed-release capsules (Cymbalta, generic), Drizalma Sprinkle 60 mg delayed-release capsules

No overrides recommended.

Desvenlafaxine 25 mg extended-release tablets (Pristiq, generic)

1. If the individual requires the dose to be divided twice daily, approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 400 mg per day.
2. If the individual is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 400 mg per day.

Desvenlafaxine 50 mg extended-release tablets, Khedezla 50 mg extended-release tablets, desvenlafaxine 50 mg extended-release tablets (Pristiq, generic)

1. If the individual requires the dose to be divided twice daily, approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 400 mg per day.
2. If the individual is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 400 mg per day.

Desvenlafaxine 100 mg extended-release tablets, Khedezla 100 mg extended-release tablets, desvenlafaxine 100 mg extended-release tablets (Pristiq, generic)

1. If the individual has been started and stabilized on a dose greater than 100 mg per day or if the individual has been receiving 100 mg daily and the dose is now being increased, approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 400 mg per day.

Venlafaxine HCl 25 mg immediate-release tablets

1. If the individual is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 375 mg per day.

Venlafaxine HCl 37.5 mg immediate-release tablets

1. If the individual is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 375 mg per day.

used), approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 375 mg per day.

Venlafaxine HCl 50 mg immediate-release tablets

1. If the individual is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery not to exceed a dose of 375 mg per day.

Venlafaxine HCl 75 mg immediate-release tablets

1. If the individual is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 375 mg per day.
2. If the individual has been started and stabilized on a dose greater than 300 mg per day or if the individual has been receiving 300 mg per day and the dose is now being increased, approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 375 mg per day.

Venlafaxine HCl 100 mg immediate-release tablets

No overrides recommended.

Venlafaxine HCl 37.5 mg extended-release capsules (Effexor XR, generic)

1. If the individual is taking 37.5 mg twice daily, approve 60 capsules per dispensing at retail and 180 capsules per dispensing at home delivery.
2. If the individual is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply at home delivery, not to exceed a dose of 375 mg per day.

Venlafaxine HCl 75 mg extended-release capsules (Effexor XR, generic)

1. If the individual is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 375 mg per day.
2. If the individual has been started and stabilized on a dose greater than 225 mg per day or if the individual has been receiving 225 mg daily and the dose is now being increased, approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 375 mg per day.

Venlafaxine HCl 150 mg extended-release capsules (Effexor XR, generic)

1. If the individual has been started and stabilized on a dose greater than 225 mg per day or if the individual has been receiving 225 mg per day and the dose is now being increased, approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 300 mg per day.

Venlafaxine HCl 37.5 mg extended-release tablets (generic)

1. If the individual is taking 37.5 mg twice daily, approve 60 capsules per dispensing at retail, and 180 tablets per dispensing at home delivery.
2. If the individual is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply at home delivery, not to exceed a dose of 375 mg per day.

Venlafaxine HCl 75 mg extended-release tablets (generic)

1. If the individual is taking 75 mg twice daily, approve 60 capsules per dispensing at retail, and 180 tablets per dispensing at home delivery.
2. If the individual is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 375 mg per day.

If the individual has been started and stabilized on a dose greater than 225 mg per day or if the individual has been receiving 225 mg per day and the dose is now being increased, approve up a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 375 mg per day.

Venlafaxine HCl 150 mg extended-release tablets (generic)

1. If the individual is taking 300 mg per day (as a single or divided dose), approve 60 tablets per dispensing at retail and 180 tablets per dispensing at home delivery.

Venlafaxine HCl 225 mg extended-release tablets

No overrides recommended.

Venlafaxine besylate 112.5 mg extended-release tablets

1. If the individual is taking 225 mg per day (as a single or divided dose), approve 60 tablets per dispensing at retail and 180 tablets per dispensing at home delivery.

Fetzima 20 mg extended-release capsules

1. If the individual is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 100 mg per day.

Note: For example, if an individual is taking 60 mg daily, this would require one 20 mg capsule plus one 40 mg capsule. So this override would approve 90 of the 20 mg capsules. As another example, if an individual is taking 100 mg daily, this would require one 20 mg capsule plus one 80 mg capsule. This override would approve 150 of the 20 mg capsules.

Fetzima 40 mg extended-release capsules

1. If the individual requires a dose of 40 mg twice daily, approve 60 capsules for a 30-day supply per dispensing at retail and 180 capsules for a 90-day supply per dispensing at home delivery.
2. If the individual requires a dose of 40 mg three times daily, approve 90 capsules for a 30-day supply per dispensing at retail and 270 capsules for a 90-day supply per dispensing at home delivery.

Fetzima 80 mg and 120 mg extended-release capsules and Fetzima Titration Pack

No overrides recommended.

Savella 12.5 mg tablets

1. If the individual is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 200 mg per day.

Savella 25 mg tablets

1. If the individual is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 200 mg per day.

Savella 50 mg tablets

1. If the individual is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve a quantity sufficient to allow for a 30-day supply per dispensing at retail and a 90-day supply per dispensing at home delivery, not to exceed a dose of 200 mg per day.

Savella 100 mg tablets and Titration Pack

No overrides recommended.

Conditions Not Covered

Any other exception is considered not medically necessary.

Background

Overview

All of the serotonin and norepinephrine reuptake inhibitors (SNRIs), with the exception of Savella, are indicated for the treatment of Major Depressive Disorder (MDD).¹⁻¹¹ Some of the SNRIs carry additional indications (Table 1).

Table 1. FDA-Approved Indications in Adults.¹⁻¹¹

Brand (generic)	MDD	GAD	Social Anxiety Disorder	Panic Disorder	DPN Pain	Chronic Musculoskeletal Pain	Fibromyalgia
Cymbalta® (duloxetine delayed-release capsules, generic)	X	X [^]			X	X	X [#]
duloxetine 40 mg delayed-release capsules (generic to discontinued Irenka™)	X	X [^]			X	X	
Drizalma Sprinkle™ (duloxetine delayed-release capsules)	X	X [^]			X	X	X
Desvenlafaxine extended-release tablets (brand product)	X						
Khedeza™ (desvenlafaxine extended-release tablets)	X						
Pristiq® (desvenlafaxine succinate extended-release tablets, generic)	X						
venlafaxine HCl immediate-release tablets (generic to discontinued Effexor®)	X						
venlafaxine besylate extended-release tablets (brand product)	X	X					

Table 1. FDA-Approved Indications in Adults.¹⁻¹¹

Brand (generic)	MDD	GAD	Social Anxiety Disorder	Panic Disorder	DPN Pain	Chronic Musculoskeletal Pain	Fibromyalgia
Effexor XR® (venlafaxine HCl extended-release capsules, generic)	X	X	X	X			

Venlafaxine HCl extended-release tablets (generic only)	X		X				
Fetzima® (levomilnacipran extended-release capsules)	X						
Savella® (milnacipran tablets)							X

MDD – Major Depressive Disorder; GAD – Generalized Anxiety Disorder; DPN – Diabetic Peripheral Neuropathy; ^ Approved for use in patients ≥ 7 years of age with GAD; # Approved for use in patients ≥ 13 years of age with fibromyalgia.

Dosing and Availability

Dosing and availability for the SNRIs is in the Drug Quantity Limits table.

References

1. Cymbalta® capsules [prescribing information]. Indianapolis, IN: Lilly; July 2021.
2. Desvenlafaxine extended-release tablets [prescribing information]. Cranbury, NJ: Sun Pharmaceuticals; September 2021.
3. Drizalma Sprinkle™ delayed-release capsules [prescribing information]. Cranbury, NJ: Sun Pharmaceutical; July 2021.
4. Irenka™ delayed-release capsules [prescribing information]. Baltimore, MD: Lupin Pharma; June 2015.
5. Effexor XR® extended-release capsules [prescribing information]. Philadelphia, PA: Pfizer; November 2021.
6. Fetzima® extended-release capsules [prescribing information]. Irvine, CA: Allergan; September 2021.
7. Khedezla™ extended-release tablets [prescribing information]. Morristown, NJ: Pernix; August 2021.
8. Pristiq® extended-release tablets [prescribing information]. Philadelphia, PA: Pfizer; November 2021.
9. Savella® tablets [prescribing information]. Irvine, CA: Allergan; February 2022.
10. Effexor® tablets [prescribing information]. Philadelphia, PA: Wyeth; December 2012.
11. Venlafaxine hydrochloride extended-release tablets [prescribing information]. Cranbury, NJ: Sun Pharmaceutical; October 2021.
12. Venlafaxine besylate extended-release tablets [prescribing information]. Morristown, NJ: Almatica; June 2022.

Revision History

Type of Revision	Summary of Changes	Approval Date
Annual Revision	<p>Desvenlafaxine ER tablets This branded product from Macoven was removed from policy (obsolete since April 2016).</p> <p>Desvenlafaxine 25 mg extended-release tablets (Pristiq, generic), Desvenlafaxine 50 mg extended-release tablets, Khedezla 50 mg extended-release tablets, desvenlafaxine 50 mg –extended release tablets (Pristiq, generic) Updated override criteria to add “not to exceed a dose of 400 mg per day” for a patient who requires the dose to be divided twice daily, to approve a quantity sufficient for a 30-day supply.</p> <p>Desvenlafaxine 100 mg extended-release tablets, Khedezla 100 mg extended-release tablets, desvenlafaxine 100 mg extended-release tablets (Pristiq, generic), venlafaxine 75 mg extended-release tablets (generic) The language regarding documentation of the patient’s previous dose was removed, as documentation is not required.</p> <p>Fetzima 40 mg extended-release capsules</p>	06/01/2022

	Override criteria for a patient who requires a dose of 40 mg twice daily or three times daily was updated to approve 90-capsules as a 30-day supply per dispensing (previously approved a quantity sufficient).	
Selected Revision	<p>Policy was updated to reflect the existing quantity limits when a product is obtained via home delivery.</p> <p>Fetzima Titration Pack: The quantity limit at home delivery was changed from 3 packs (84 capsules) per dispensing to 1 pack (28 capsules) per dispensing. There was no change to the retail quantity limit of 1 pack (28 capsules) per dispensing.</p> <p>Savella Titration Pack: The quantity limit at home delivery was changed from 3 packs (165 tablets) per dispensing to 1 pack (55 tablets) per dispensing. There was no change to the retail quantity limit of 1 pack (55 tablets) per dispensing.</p> <p>Duloxetine 20 mg and 30 mg delayed-release capsules (Cymbalta, generic) and Drizalma Sprinkle 20 mg and 30 mg delayed-release capsules: Updated override criteria to add “not to exceed a dose of 120 mg per day” for a patient who is taking a dose that does not correspond to a commercially-available dosage form.</p> <p>Venlafaxine besylate: A quantity limit for venlafaxine besylate (branded product) was added to the policy. Override criteria apply.</p>	08/03/2022

“Cigna Companies” refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc. and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2023 Cigna.